STUDY QUESTION: Is polycystic ovary syndrome (PCOS) associated with anogenital distance (AGD), a biomarker of fetal androgen exposure, in adult Mediterranean women?
Introduction
Polycystic ovary syndrome (PCOS) accounts for most cases of anovulatory symptoms and hyperandrogenism in women (Azziz et al., 2004; Carmina et al., 2006) . Worldwide prevalence of PCOS in women of reproductive age ranges from 4 to 21% depending on the diagnostic criteria (Lizneva et al., 2016) . PCOS is typified by intraovarian androgen excess that stimulates the growth of small follicles while hindering the selection of a dominant follicle (Jonard and Dewailly, 2004) . The diagnosis of PCOS has life-long implications with increased risk for infertility, metabolic syndrome, Type 2 diabetes mellitus, cardiovascular disease and endometrial carcinoma (Fauser and Bouchard, 2011; Barry et al., 2014) .
Although the etiopathogenesis of PCOS is still unclear, the prevailing concept is that PCOS is the result of intrinsic ovarian genetic characteristics that interact with one or more congenital or environmental factors to cause dysregulation of steroidogenesis (Ehrmann, 2005) . Hormonal imbalance, especially intrauterine androgen excess during early development, can be related to the development of the PCOS phenotype in animal models (Padmanabhan and Veiga-Lopez, 2013) . Several human observational studies have shown an association between the fetal hormonal environment and subsequent development of PCOS (Cresswell et al., 1997; Ibáñez et al., 1998; Michelmore et al., 2001; Pandolfi et al., 2008; Melo et al., 2010; Davies et al., 2012) . The ethnic and geographic heterogeneity (i.e. variations in prevalence and clinical manifestations) of this disorder suggests an important role for environmental and lifestyle factors in its etiology (Merkin et al., 2016; Rutkowska and Diamanti-Kandarakis, 2016) .
Anogenital distance (AGD) is a sexually dimorphic attribute in mammals, almost twice as long in males as in females and a marker of intrauterine androgen environment (Greenham and Greenham, 1977; Kurzrock et al., 2000) . In human studies, AGD is an anthropometric biomarker of prenatal exposure to endocrine-disrupting chemicals (Swan et al., 2005 Bornehag et al., 2014) and to androgens during the development of the reproductive system (Dean and Sharpe, 2013; Jain and Singal, 2013) . Fetal exposure to stressful life events lead to a longer (more masculine) AGD in infant girls (Barrett et al., 2013) , whereas exposure to anti-androgens leads to a shorter (more feminine) AGD in infant males (Swan et al., 2005 . At reproductive age women, AGD length is related to female reproductive function (Mendiola et al., 2012; Mira-Escolano et al., 2014a , 2014b Barrett et al., 2015) . Recently, Barrett et al. (2016) reported that newborn daughters of women with PCOS had a longer AGD and Wu et al. (2017) have shown that the presence of PCOS is associated with longer AGD measurements in Chinese women. A strong association between shorter AGD measurement and presence of endometriosis (an estrogen-dependent disease) has also been reported (Mendiola et al., 2016) . However, there is still controversy over what AGD means in humans (Foster et al., 2017) . We hypothesize that a prenatal androgenic environment resulting in relatively longer AGD will be associated with presence of PCOS. The aim of this study was therefore to evaluate the relationship between AGD measurements, as a biomarker of prenatal androgen milieu, and the presence of PCOS in adult Mediterranean women.
Methods

Study population
This was a case-control study conducted from September 2014 to May 2016 at the Department of Obstetrics and Gynecology of the University Clinical Hospital 'Virgen de la Arrixaca' in the Murcia Region (southeastern Spain). All women, cases and controls, between 18 and 40 years old, were excluded from the study if they: were pregnant or lactating, had been exposed to oncological treatment, had genitourinary prolapse or endocrine disorders (e.g. Cushing's syndrome, congenital adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia and hyper-and hypo-thyroidism) or were taking any hormonal medication, including contraception, during the 3 months prior to the study. Cases (n = 126) were women attending the gynecology unit of the hospital, and included prevalent and incident (newly diagnosed) cases. Cases, whether incident or prevalent, were included only if a diagnosis could be established following the Rotterdam criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004), including medical history with a modified Ferriman-Galwey (mF-G) score (Ferriman and Gallwey, 1961) , transvaginal ultrasound (TVUS) and reproductive hormone levels. Briefly, a diagnosis of PCOS required completion of at least two of the following three criteria: (i) hyperandrogenism either biochemical (total testosterone level ≥ 2.6 nmol/l) or clinical (mF-G score ≥ 12) (Afifi et al., 2017) with or without acne or androgenic alopecia; (ii) oligo-and/or anovulation (menstrual cycles > 35 days or amenorrhea > 3 months); (iii) polycystic ovarian morphology (POM) on TVUS (≥12 follicles measuring 2-9 mm in diameter, mean of both ovaries) (Conway et al., 2014) . Moreover, the following phenotypic subtypes of PCOS were also assessed (National Institutes of Health, 2012): hyperandrogenism + oligo/amenorrhea; hyperandrogenism + POM; oligo/amenorrhea + POM; and hyperandrogenism + oligo/amenorrhea + POM.
Controls (n = 159) were women without PCOS (or other major gynecological conditions, e.g. endometriosis) attending the gynecological outpatient clinic for routine gynecological examinations. The same procedures were performed in both cases and controls: anamnesis and questionnaires, physical examination including AGD measurements, and TVUS and blood draw between Days 2-5 of the menstrual cycle. The diagnosis of PCOS versus controls was performed following the Rotterdam criteria once biochemical analyses were available. Written informed consent was obtained from all subjects. This study was approved by the Ethics Research Committee of the University of Murcia and the Clinical University Hospital (no. 770/2013, approved 3 October 2013).
Gynecological history, anthropometric and hormonal measurements
Case subjects and controls were interviewed in-person by gynecologists. All participants filled out health questionnaires, gynecological and obstetrical history, and underwent a physical and gynecological examination including TVUS and blood draw at a scheduled clinical visit. Weight and height were measured using a digital scale (Tanita SC 330-S, London, UK) and BMI was calculated. Uterine and ovarian morphology were evaluated with TVUS (Voluson E8 ® and 4-9 MHz transducer; General Electric Healthcare, USA).
Two gynecologists performed all clinical evaluations using the same methodology. One non-fasting blood sample was drawn between 8 and 10 a.m. on the same day of the clinical appointment and during the early follicular phase (Days 2-5). The blood serum was separated by centrifugation, coded and frozen at −80°C until analysis. All samples were analyzed for hormones in the same laboratory at the 'Virgen de la Arrixaca' University Hospital (Murcia, Spain). Serum levels of follicle-stimulating hormone (FSH), LH and testosterone were determined using a time-resolved electrochemiluminiscence immunoassay (Roche Diagnostic Corporation, Indianapolis, IN, USA). Assay sensitivities were 0.10 IU/l for FSH and LH and 0.1 nmol/l for T.
Anogenital measures
Women rested in the lithotomy position with thighs at 45°to the examination table. Using a digital caliper (Stainless Steel Digital Caliper, VWR ® International, LLC, West Chester, PA, USA), AGD AC was measured from the anterior clitoral surface to the upper verge of the anus, and AGD AF was measured from the posterior fourchette to the upper verge of the anus ( Fig. 1 ) (Mendiola et al., 2016) . Two gynecologists unaware of the patient's status measured each distance three times. Average values of the six measurements were used in the analyses.
Statistical analyses
Descriptive statistics are shown using crude data. In bivariate analyses, continuous variables were compared using unpaired Student T or MannWhitney U-tests, and categorical variables were compared with chi-squared test. Multiple linear regression analysis was employed to examine associations between AGD measurements and reproductive hormone levels and number of antral ovarian follicles in PCOS women and controls. Unconditional multiple logistic regression was used to explore the association between presence of PCOS and phenotypic subtypes (yes/no) and AGD (in tertiles from the whole distribution of cases and controls, with the lowest tertile as the reference category) using odds ratios (OR) and 95% CI. Weight (kg) and age (years) were included as potential confounders in the model, and episiotomy was included as covariate that may affect AGD. Tests for trend in the ORs across exposure strata for AGD measures were calculated using logistic models that included categorical terms as continuous variables. Coefficients of variation (%CV) were used to assess intra-and inter-examiner variability in AGD measurements. To evaluate the discriminating ability of AGD to detect PCOS, ROC curves were generated using maximum likelihood estimation to fit a binomial ROC curve to continuously distributed data. ROC curves were created comparing AGD AC measurements and presence of PCOS versus controls. To calculate sensitivity, specificity, positive and negative likelihood ratios, AGD measurements were dichotomized by using optimal cut-off points based on maximum Youden Index (J) value (Ruopp et al., 2008) . Analyses were carried out with IBM SPSS 19.0 (IBM Corporation, Armonk, New York, USA). All tests were two-tailed at 0.05 significance level.
Results
Overall, 97% of the women were Caucasian, controls were 3.3 years older than cases (30.7 versus 27.4 years old) and, as expected, cases were heavier than controls (69.3 versus 63.6 kg). Reproductive hormones levels and number of antral follicles were significantly different between both groups, as were symptoms of PCOS (Table I) . Parous controls presented a higher percentage of episiotomy compared to parous cases (14% versus 5.6%). Other demographic and lifestyle variables were comparable between both groups (Table I) . AGD AC and AGD AF presented normal distributions and were correlated [Pearson correlation (r) = 0.60, P < 0.001]. Intra and inter-examiner CVs were below 5% and intraclass correlation coefficients above 0.95 for both AGD measurements. Cases showed significantly longer AGD AF (27.8 versus 26.5 mm; P, value = 0.048) and AGD AC (80.5 versus 76.0 mm; P, value = 0.001) compared to controls in the bivariate analyses. In within group comparisons and the entire study population, there were no significant associations between AGD measures and women's reproductive hormone levels and number of antral ovarian follicles (Table II) . Table III shows AGD measurements in tertiles and ORs. In the final adjusted models, AGD AC , but not AGD AF , was associated with the presence of PCOS (P, values, 0.002-0.008). Women with AGD AC in the upper compared to the lowest tertile were 2.9-times (95% CI 1.4-5.9; P, trend = 0.008) more likely to have PCOS. AGD AC measures were also statistically significantly associated with all the different phenotypic subtypes of PCOS (ORs = 3.1-5.1; P, values < 0.05), showing a 'dose-response' relationship with the severity of the phenotypic subtypes (Table IV) . With regard to the diagnostic accuracy of AGD AC measurements, for all PCOS cases (n = 126) and controls (n = 159), the AUC of AGD AC was 0.62 (95% CI 0.55-0.68) (Fig. 2) with an optimal cut-off of the predicted probability of 81.9 mm. The sensitivity of this model was 50%, specificity was 73% and the positive and negative likelihood ratios were 1.9 and 0.68, respectively.
Discussion
We found a significant association between AGD AC and the presence of PCOS, suggesting that the intrauterine hormonal environment during fetal life may play an important role in the development of PCOS.
To the best of our knowledge, this is the first study to explore this relationship in Mediterranean women and to report significant associations with phenotypic subtypes of PCOS.
Twin studies have suggested that genetic influences may explain over 70% of PCOS etiopathogenesis (Vink et al., 2006; Rosenfield, 2007) . In addition, most adolescents with PCOS have either a mother with PCOS, or a father with metabolic syndrome (Leibel et al., 2006) . The prevalence of PCOS in mothers and sisters of PCOS women is 20-40%, considerably higher than that seen in the general population, and this has been interpreted as supporting a potential genetic basis for PCOS (Legro et al., 1998; Kahsar-Miller et al., 2001 Have you ever smoked? c Did you ever drink alcoholic beverages with a frequency of at least one a month? ovarian steroidogenesis, insulin metabolism, gonadotrophin secretion and ovarian follicle development, resulting in a higher risk of PCOS in adult life (Filippou and Homburg, 2017) . Therefore, although heritability is generally assumed to reproduce the effects of inherited genomic variation, it could also reproduce the effects from combined predisposing intrauterine hormonal environments.
Many experimental studies in animals (rodent, sheep, monkey) show that elevated prenatal testosterone levels early in intrauterine life lead to reproductive and metabolic disruptions that mimic those seen in women with PCOS (Abbott et al., 2010; Veiga-Lopez et al., 2011; Dumesic et al., 2014; Ramaswamy et al., 2016; Vyas et al., 2016; Walters, 2016) . Mechanistic studies indicate that the neuroendocrine consequences of androgen exposure involve suppression of estrogen induction of the hypothalamic progesterone receptors; when androgen is given prenatally, this effect persists into adulthood (Foecking et al., 2008) .
Exposure to endocrine-disrupting chemicals that mimic endogenous hormones may also compromise fetal programming leading to PCOS and other adverse health effects, including potential transgenerational transmission (Barrett and Sobolewski, 2014; Rutkowska and DiamantiKandarakis, 2016) . Clinical studies have shown associations between intrauterine hyperandrogenic environment (e.g. congenital adrenal hyperplasia) and longer AGD in female infants (Callegari et al., 1987) . A longer AGD has been related to higher antral follicle count (Mendiola et al., 2012) and higher testosterone levels (Mira-Escolano et al., 2014b). Furthermore, in young women, longer AGD has been related to irregularities in their mother's menstrual cycle before pregnancy (Mira-Escolano et al., 2014a) , implying that the intrauterine environment may generate a long-lasting influence in the reproductive tract of female descendants. Recently, Barrett et al. (2016) reported that newborn daughters of women with PCOS had longer AGD, suggesting that AGD could be a potential marker of the downstream PCOS risk. Wu et al. (2017) have shown that the presence of PCOS is associated with longer AGD measurements in Chinese women. Our findings are consistent with the latter, offering further evidence that prenatal androgens may contribute to presence of PCOS in adulthood, including a 'dose-response' association with the severity of the phenotypic subtypes. Overall, AGD measurements were relatively longer in the Chinese women compared to ours, and in our study population, AGD AC moderately discriminated the presence of PCOS and could be a useful clinical tool. Apart from representing another ethnic group, our study may present higher generalizability as the controls represent the general female population, including women with vaginal deliveries and were not restricted to women with regular menstrual cycles and without clinical evidence of hyperandrogenism. That difference may explain why we obtained significant though weaker associations between AGD and presence of PCOS. Contrary to Wu et al. (2017) , we did not observe an association between AGD and reproductive hormone levels within groups or the entire study population. Ethnicity may be a partial explanation though further research is required. Our findings are also consistent with previous studies on finger length ratio (2D:4D ratio) reporting that PCOS women have reduced length of the 2D:4D ratio that correlates with hyperandrogenism and ovarian volume (Lutchmaya et al., 2004; Cattrall et al., 2005; Palomba et al., 2012) . However, other authors (e.g. Lujan et al., 2010) have found no relationships between 2D:4D ratios and clinical phenotypes of PCOS. Our results are also coherent with a recent study showing an association between shorter AGD and the presence and severity of endometriosis, which has been hypothesized to be etiologically associated with exposure to estrogen in utero (Mendiola et al., 2016) . All these findings provide additional support to consider AGD as a useful anthropometric biomarker of intrauterine hormonal milieu both for epidemiological and clinical studies.
Our study presents some limitations. Measurement and selection and bias must always be considered. However, the controls were women attending the public hospital department in the same study period, and they came from the same population as the cases. AGD measurements were carried out by two gynecologists who were not involved in the PCOS diagnosis and who were uninformed of the patient's status. Misclassification of PCOS status may have occurred but, if present, it would have contributed to underestimating the true magnitude of the relationship. With a case-control design, we cannot rule out the possibility that elevated androgens during childhood or adulthood, as well as other effects of factors during critical periods of development (e.g. hormonal medication or fetal exposure to stressful life events), resulted in longer AGD in women with PCOS. We found significant relationships with the presence of PCOS for AGD AC , but not for AGD AF. AGD AF measurement tends to be a more difficult measurement due to uncertainty about the appropriate landmarks. For instance, in newborns, AGD AF has shown the greatest betweencentre differences in recent investigations Swan et al., 2015) . However, a few studies have shown associations for AGD AC in females (Mendiola et al., 2012) and for the long (equivalent) measurement (anopenile distance) in male newborns (Swan et al., 2005 .
In conclusion, our results provide the first evidence of an association between AGD, as a biomarker of intrauterine androgen environment, and the presence of PCOS and its phenotypic subtypes in adult Mediterranean women. Our findings, if replicated, could have important implications for PCOS in terms of prevention, clinical practice and future research.
